DelveInsight’s ‘Global Messenger RNA (mRNA)-based Vaccines and Therapeutics – Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the mRNA-based Vaccines and Therapeutics, along with its historical and forecasted epidemiology and market trends in North America, Europe, Asia, and ROW (rest of the world).
The mRNA-based Vaccines and Therapeutics report provides emerging drugs analysis, mRNA-based Vaccine and Therapeutics market share of the individual diseases, current and forecasted mRNA-based Vaccines, and Therapeutics market size from 2021 to 2030 segmented by major regions like North America, Europe, Asia, and ROW. The report also covers current mRNA-based Vaccines and Therapeutics market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2018–2030
Unlike deoxyribonucleic acid (DNA), ribonucleic acid (RNA) is a single-stranded molecule. An RNA strand has a backbone made of alternating sugar (ribose) and phosphate groups. Different types of RNA exist in the cell: messenger RNA (mRNA), ribosomal RNA (rRNA), and transfer RNA (tRNA). In clinical medicine today, RNA-based treatments, including RNA molecules as drugs and RNA-targeted small molecules, and others give unique ways to extend the spectrum of therapeutic goals. Since its inception, vaccination has been considered the most effective method of preventing infectious diseases. However, there are several disadvantages of conventional vaccines. Compared to traditional vaccines that specifically insert antigenic proteins that trigger an immune response in the host, mRNA vaccines introduce mRNAs that encode disease-specific antigens and exploit host cell protein synthesis machinery to generate antigens that stimulate an immune response.
The mRNA is like a template that holds information cells used to generate various proteins. Decades of comprehensive investigation in molecular biology and biochemistry have culminated in introducing therapeutic mRNA as a novel drug type. It is worth noting that mRNA is the only vaccine format that is quite robust in terms of production. The most recent research on mRNA vaccines encompasses infectious diseases and cancer, for which many early-stage clinical trials have been performed.
In addition, some early studies are assessing the potential of RNA vaccines for rare diseases as well. In the case of infectious diseases, experimental mRNA vaccine clinical trials have been performed or underway for cytomegalovirus, HIV-1, rabies, Zika virus, and, most recently, COVID-19. In order to address the current global coronavirus epidemic, tremendous initiatives have been undertaken to improve preventive measures, which also include the accelerated development of mRNA vaccines. In the future, mRNA-based therapies could help treat various diseases such as melanoma, non-small cell lung cancer (NSCLC), advanced malignancies (solid tumors), ornithine transcarbamylase deficiency, cystic fibrosis, and several others.
The remarkable acceleration of RNA vaccine research triggered by COVID-19 is likely to continue to drive the production of RNA vaccines against influenza virus, rabies, Zika, Chikungunya, and other pathogens for which investigational assets are in the pipeline at different development stages.
Last year (in 2020), the world was struck by a worldwide pandemic, and the production of mRNA vaccines progressed at a tremendous pace. Several organizations have spent time and money to create a strategy that would eventually solve this issue. For this, a research and development partnership between several organizations has been established to produce mRNA-based vaccines.
In December 2020, Pfizer and BioNTech received emergency use authorization (EUA) for their mRNA vaccine BNT162b2 to prevent COVID-19 (16 years of age or older) in the United States. The US Food and Drug Administration (FDA) based its decision on the totality of scientific evidence shared by the companies, including data from a pivotal Phase III clinical study which showed 95% efficacy. After Pfizer, the US FDA cleared Moderna’s vaccine (mRNA-1273) for COVID-19 in individuals 18 years of age or older. Before this, no mRNA vaccines had ever reached this late stage of clinical development. Approval of these vaccines is an outstanding milestone for mRNA class.
In a nutshell, it can be said that it is just the beginning of this new class. At present, mRNA vaccines represent a promising alternative to conventional vaccines. The clinical trial evidence to date for COVID-19 indicates that the mRNA vaccines have a high potential to be quick, safe, and effective as a new platform.
The mRNA-based Vaccines and Therapeutics epidemiology division provides insights about historical and current mRNA-based Vaccines and Therapeutics patient pool and forecasted trends for North America, Europe, Asia, and ROW. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
As mentioned earlier, the majority of emerging mRNA-based Vaccine and Therapeutic assets are targeting infectious diseases like COVID-19, cytomegalovirus, human metapneumovirus (hMPV), and the parainfluenza type 3 (PIV3), and several others. Few companies are also investigating their mRNA-based candidates for cancer types such as melanoma, lung cancer, solid tumors/lymphoma, and advanced ovarian carcinoma. The disease epidemiology covered in the report provides historical as well as forecasted global epidemiology scenario of targeted indications with mRNA-based vaccines and therapeutics segmented as total cases of selected indications for mRNA-based vaccines and therapeutics (Infectious diseases, cancer types, and others), total diagnosed cases of selected indications for mRNA-based vaccines and therapeutics, number of patients eligible for mRNA-based vaccines and therapeutics, and total treated cases of targeted therapies using mRNA-based vaccines and therapeutics covering North America, Europe, Asia, and ROW (rest of the world) from 2018 to 2030.
Region-wise mRNA-based Vaccines and Therapeutics Epidemiology
The epidemiology segment provides the information regarding the selected indications targeted with mRNA-based Vaccines and Therapeutics, along with key findings across North America, Europe, Asia, and ROW (rest of the world) from 2018 to 2030.
Report’s drug chapters encompass the detailed analysis of mRNA-based Vaccines and Therapeutics marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the mRNA-based Vaccines and Therapeutics clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
In the past, the US FDA has approved several classes of RNA therapies such as RNA aptamer (Macugen), antisense RNAs (Eteplirsen and Spinraza), and one small interfering RNA (Onpattro). All these approvals are milestones achieved in the RNA therapeutics class and have paved a road for other RNA classes. To date, for several infectious diseases and genetic disorders, prophylactic and therapeutic care options remain limited, cost-intensive, or inadequate. Therefore, the novel, mRNA-based preventive/therapeutic approach for such indications has exceptional potential.
At present, pharmaceutical companies are thoroughly working to utilize mRNA class to ‘prevent’ (for example; COVID-19 and other infectious diseases such as CMV infection, RSV, HIV, etc.) and ‘treat’ (various cancer types, rare indications, etc.) several health concerns, as a new frontier of medicine. This therapeutic class is gaining global attention, and front-runners of this segment, i.e., Moderna Therapeutics, BioNTech, CureVac, Arcturus, and Translate Bio, are likely to experience the well-deserved market space, as the global demand is expected to rise for their products due to the outbreak of COVID-19. Apart from this, an increase in the number of prominent market players conducting clinical trials for vaccines and therapies for multiple indications will be going to drive the market of mRNA-based vaccines and therapies globally. These companies have multiple assets starting from Prophylaxis to Therapeutics for various indications.
BNT162b2: Pfizer-BioNTech
In December 2020, UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted emergency use approval to the Pfizer-BioNTech’s COVID-19 vaccine (BNT162b2). After the approval, the United Kingdom became the first country globally to have a COVID-19 vaccine approved for emergency use. Later, the US FDA also granted authorization to the Pfizer-BioNTech coronavirus vaccine for emergency use.
mRNA-1273: Moderna
Moderna’s COVID-19 vaccine, mRNA-1273, has received a EUA from the US FDA in December 2020. Apart from this, the European Medicines Agency (EMA) has recommended mRNA-1273 for authorization in the European Union (EU) as well.
Note: Detailed Current therapies assessment will be provided in the full report
Based on application, mRNA-based vaccines can be categorized into prophylactic vaccines and therapeutic vaccines. Moderna has prophylactic vaccines currently under investigation for CMV (Phase II), hMPV/PIV3 (Phase Ib pediatrics, and Phase I [adults]), Zika, RSV, Epstein-Barr virus (EBV), Influenza, HIV, and Nipah.
Furthermore, mRNA is also being utilized as a therapeutic vaccine in the case of several cancer types. It is expected that these therapeutic vaccines could offer the potential for durable responses through the engagement of the patient’s immune system. Several vaccines are currently in the pipeline for the same, for example, mRNA-4157 ([Personalized cancer vaccine [PCV]), mRNA-5671 (KRAS vaccine), CV9202 (NSCLC), RG6180 (first-line melanoma), and others.
Besides these, there are several Immuno-Oncology (I-O) mRNA-based therapeutic candidates under development. It is hoped that by administering mRNA-based therapies (for example, mRNA-2416 [ovarian cancer], mRNA-2752 [advanced solid tumor malignancies and lymphoma]) directly into tumors, anti-cancer T-cell responses can be stimulated in cancer patients. Also, mRNA-based therapies are not limited to only cancer; they are also utilized for other diseases.
Along with these prophylactic vaccines, Moderna has mRNA-based systemic secreted and cell surface therapeutics like mRNA-1944 for the Chikungunya virus (Phase I). These assets are in the early stages of development for indications like autoimmune hepatitis (mRNA-6981; preclinical) and autoimmune disorders (mRNA-6231; preclinical).
mRNA-based therapies can also be utilized as a regenerative therapeutic. AZD8601 is a clinical-grade VEGF-A165 mRNA-based therapy developed by AstraZeneca for patients with ischemic heart disease undergoing coronary artery bypass grafting (CABG) surgery with moderately impaired systolic function. Moderna has licensed worldwide commercial rights to AZD8601 to AstraZeneca. In the pipeline, few candidates are being investigated for rare indications. Translate Bio is currently conducting a clinical trial for CF.
• Prophylactic Vaccines
mRNA -1647: Moderna
Moderna has a diverse portfolio of mRNA-based treatments and vaccines for infectious diseases, immuno-oncology, and rare diseases. Their mRNA-1273 is already approved and launched for the prevention of COVID-19. The company is investigating another product, i.e., mRNA-1647, to prevent cytomegalovirus (CMV) infection. Moderna’s mRNA vaccine combines six mRNAs (five encodings for the pentamer complex and one encoding for gB [glycoprotein B]) into one vial.
The company is also exploring potential combination vaccines against the respiratory syncytial virus (RSV) and the human metapneumovirus (hMPV). Recently, i.e., in January 2021, Moderna provided a business update and announced three new development programs in infectious disease vaccines against seasonal flu, HIV, and the Nipah virus. For the Flu vaccine, the company is expecting to investigate mRNA-1010, mRNA-1020, mRNA-1030 in Phase I for type A and type B in 2021. Besides, the company expects to begin Phase I clinical trials for both mRNA-1644 and mRNA-1574 in 2021 for HIV. Furthermore, mRNA-1215 which was co-developed by Moderna and the NIH’s Vaccine Research Center (VRC), is also among the development program.
CVnCoV: CureVac
CureVac’s mRNA-based prophylactic vaccine candidate known as CVnCoV against COVID-19 is also under development. A pivotal Phase IIb/III study has been initiated in December 2020 to access a 12 µg dose of CVnCoV in two parts: an initial Phase IIb trial which is expected to merge into a Phase III efficacy trial seamlessly. Both the Phase IIb and Phase III trials are randomized, observer-blind, placebo-controlled studies in adults over 18 years or older.
• Cancer (Lung Cancer, Melanoma, and others)
• Cancer Therapeutic Vaccines
mRNA-4157- Moderna
Moderna is investigating their personalized cancer vaccine candidate mRNA-4157 in patients with unresectable solid tumors. In November 2020, the company also presented interim data from Phase I dose expansion cohort of mRNA-4157 combined with pembrolizumab at the Society for Immunotherapy of Cancer’s Annual Meeting (SITC 2020).
CV9202 (BI 1361849): CureVac
CV9202, also known as BI 1361849, is a self-adjuvanting mRNA vaccine, which targets six antigens commonly expressed in NSCLC. CV9202 is currently being studied in a Phase I/II, open-label two-arm clinical trial to evaluate the safety and preliminary efficacy of the addition of a vaccine therapy to one or two checkpoint inhibitors for NSCLC.
RG6180 or BNT-122: BioNTech/Roche (Genentech)
RG6180, also known as BNT-122, is an Individualized neoantigen-specific therapy (iNeST). This candidate is an mRNA-based, individually tailored, personalized cancer vaccine. Each vaccine will be made using unique neoantigen signatures from an individual patient’s tumor, which is expected to elicit an effective immune response against that patient’s tumor. A Phase II clinical trial is evaluating iNeST for the treatment of first-line melanoma (previously untreated advanced melanoma). In addition to this, this candidate is also being investigated in locally advanced or metastatic solid tumors as a monotherapy and in combination with atezolizumab in Phase I.
• Immuno-Oncology (I-O) mRNA-based therapeutic candidates
mRNA-2416: Moderna
Moderna has initiated a Phase I/II, open-label, multicenter, dose-escalation, and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies (histologically- or cytologically-confirmed advanced/metastatic solid tumor or lymphoma).
• Others
• m-RNA-based Therapeutics
AZD8601: AstraZeneca/Moderna
AstraZeneca has initiated a Phase IIa randomized, double-blind, placebo-controlled, multicenter, sequential design study to evaluate the safety and tolerability of epicardial injections of AZD8601 during coronary artery bypass grafting (CABG) surgery. AZD-8601 is an investigational mRNA-based therapy developed by AstraZeneca/Moderna Therapeutics that encodes vascular endothelial growth factor-A (VEGF-A).
MRT5005: Translate Bio
MRT5005 is being developed to treat all CF patients, regardless of the underlying genetic mutation, including those with limited or no CFTR protein. The company is conducting a Phase I/II first-in-human, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and tolerability of single and multiple escalating doses of MRT5005 (NCT03375047). Translate Bio’s MRT5005 is the first clinical-stage mRNA product candidate designed to address the underlying cause of CF.
LUNAR-OTC (ARCT-810): Arcturus
LUNAR-OTC is a wholly-owned program of Arcturus. This mRNA replacement therapy is currently under investigation in ongoing Phase I/Ib clinical studies to treat ornithine transcarbamylase (OTC) deficiency. OTC deficiency is the most common urea cycle disorder. At present, there is no cure for OTC deficiency. The company received approval from Health Canada to enroll subjects into the Phase Ib study. Also, clinical Trial Application (CTA) for Phase II multiple-dose study on track for the second quarter.
Note: Complete and Detailed emerging therapies assessment will be provided in the final report.
Key Findings
The Global mRNA-based Vaccines and Therapeutics market size is expected to change during the forecast period 2021–2030.
North America Market Outlook
This section includes a glimpse of the mRNA-based Vaccines and Therapeutics market in North America.
Europe Market Outlook
This section provides the total mRNA-based Vaccines and Therapeutics Market Size by therapies in Europe.
Asia: Market Outlook
The total mRNA-based Vaccines and Therapeutics Market Size by therapies in Asia are provided in this section.
ROW: Market Outlook
The total mRNA-based Vaccines and Therapeutics Market Size by therapies in ROW are also mentioned.
The report provides insights into different therapeutic candidates in Phase II and Phase III stages. It also analyses mRNA-based Vaccines and Therapeutics key players involved in developing targeted therapeutics. The report also covers the detailed information of collaborations, acquisition and mergers, licensing, and patent details for mRNA-based Vaccines and Therapeutics emerging therapies.
The drugs in the pipeline include:
Infectious Disease
1. CVnCoV: CureVac
2. LUNAR-COVID19: Arcturus
3. mRNA-1647: Moderna
4. mRNA-1851: Moderna
5. mRNA-1653: Moderna
6. mRNA-1893: Moderna
Cancer
1. CV9202 (BI 1361849): CureVac
2. RG6180 or BNT-122: BioNTech/Roche (Genentech)
3. SAR441000 (BNT131): BioNTech/Sanofi
4. mRNA-2416: Moderna
Others
1. MRT5005: Translate Bio
2. LUNAR-OTC: Arcturus
3. AZD8601: AstraZeneca/Moderna
And others…..
Note: Detailed emerging therapies assessment will be provided in the final report.
This section focuses on the rate of uptake of the potential launched and emerging mRNA-based Vaccines and Therapeutic market or expected to get launched in the market during the forecast period 2021–2030. The analysis covers global mRNA-based Vaccines and Therapeutic market uptake, patient uptake by therapies, and sales of each drug. This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, allowing the comparison of the drugs based on market share and size, which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Analyst Insight
Clinical trials on various indications are ramping up as time goes by to see if mRNA treatments can help the body fight infections, genetic diseases, and even cancer. The early development and success of mRNA vaccines for COVID-19 have shown their potential, and it is possible that many pharmaceutical firms, particularly vaccine manufacturers, will become more involved in the technique. This involvement will lead to a new era in the use of mRNA for infectious diseases, rare diseases, and cancer treatment. Indeed, such progress will shift the outlook for the battle against severe outbreaks of infectious diseases.
Access and Reimbursement Scenario in mRNA-based Vaccines and Therapeutics Therapies
Proactively approaching reimbursement can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
• For COVID-19, the US Centers for Medicare and Medicaid Services (CMS) addresses reimbursement for the vaccines authorized by the US FDA under the EUA and compensation to the distributor for administration. Medicare payment rates are dependent on whether the FDA-authorized COVID-19 vaccines are administered in a single dose or multiple doses. CMS made it clear that the federal government expects public and private insurance providers to bear the expense of delivering the vaccine without cost-sharing for patients, which ensures that patients do not have to incur out-of-pocket premiums to receive the COVID-19 vaccines. As per the CMS, the Medicare reimbursement rate for the administration of COVID-19 vaccination would be USD 28.39 for the administration of single-dose vaccines. The initial dose(s) of the COVID-19 vaccine involving a sequence of two or more doses would be USD 16.94 and USD 28.39 for the final dose in the series.
To keep up with current market trends, we take KOLs and SME’s opinions working in mRNA-based Vaccines and Therapeutics domain through primary research to fill the data gaps and validate our secondary research. Their opinions help to understand and validate current and emerging therapies treatment patterns or mRNA-based Vaccines and Therapeutics market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the mRNA-based Vaccines and Therapeutics market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
1. Key Insights
2. Key Highlights from Report
3. Executive Summary of mRNA-based Vaccines and Therapeutics
4. SWOT Analysis
5. mRNA-based Vaccines and Therapeutics: Market Share (%) Distribution Overview at a Glance: By Region
6. Epidemiology and Market Methodology
7. mRNA-based Vaccines and Therapeutics: Background and Overview
8. Epidemiology and Patient Population
8.1. Epidemiology Key Findings
8.2. Assumptions and Rationale
8.3. North America Epidemiology
8.3.1. Total cases of selected indications for mRNA-based Vaccines and Therapeutics in North America
8.3.2. Total diagnosed Cases of selected indications for mRNA-based Vaccines and Therapeutics in North America
8.3.3. Number of Patients Eligible for mRNA vaccines and therapeutics in North America
8.3.4. Total treated cases of Targeted Indications Using mRNA Vaccines and Therapeutics in North America
8.4. Europe Epidemiology
8.4.1. Total Cases of selected indications for mRNA-based Vaccines and Therapeutics in Europe
8.4.2. Total diagnosed cases of selected indications for mRNA vaccines and therapeutics in Europe
8.4.3. Number of Patients Eligible for mRNA vaccines and therapeutics in Europe
8.4.4. Total treated cases of Targeted Indications Using mRNA Vaccines and Therapeutics in Europe
8.5. Asia Epidemiology
8.5.1. Total Cases of selected indications for mRNA-based Vaccines and Therapeutics in Asia
8.5.2. Total diagnosed Cases of selected indications for mRNA-based Vaccines and Therapeutics in Asia
8.5.3. Number of Patients Eligible for mRNA vaccines and therapeutics in Asia
8.5.4. Total treated cases of Targeted Indications Using mRNA Vaccines and Therapeutics in Asia
8.6. ROW Epidemiology
8.6.1. Total Cases of selected indications for mRNA-based Vaccines and Therapeutics in ROW
8.6.2. Total diagnosed Cases of selected indications for mRNA-based Vaccines and Therapeutics in ROW
8.6.3. Number of Patients Eligible for mRNA vaccines and therapeutics in ROW
8.6.4. Total treated cases of Targeted Indications Using mRNA Vaccines and Therapeutics in ROW
9. Unmet Needs
10. Key Endpoints in mRNA-based Vaccines and Therapeutics Clinical Trials
11. Marketed Therapy
11.1. BNT162b2: Pfizer and BioNTech
11.1.1. Product Description
11.1.2. Regulatory Milestones
11.1.3. Other Developmental Activities
11.1.4. Pivotal Clinical Trials
11.1.5. Ongoing Current Pipeline Activity
11.1.6. Safety and Efficacy
11.2. mRNA-1273: Moderna
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal clinical Trials
11.2.5. Ongoing Current Pipeline Activity
12. Emerging Therapies
12.1. Key Cross
12.2. mRNA-1647: Moderna
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical development
12.2.3.1. Ongoing Trials Information
12.2.4. Safety and Efficacy
12.3. CVnCoV: CureVac
12.3.1. Product Description
12.3.2. Other Developmental Activities
12.3.3. Clinical development
12.3.3.1. Ongoing Trials Information
12.3.4. Safety and Efficac
13. mRNA-based Vaccines and Therapeutics: Global Market Analysis
13.1. Key Findings
13.2. Market Outlook
13.3. Global Market Size
13.3.1. Global Market size of mRNA-based Vaccines and Therapeutics
13.3.2. Global Market size of mRNA-based Vaccines and Therapeutics by Therapies
13.4. North America Market Size
13.4.1. Total Market size of mRNA-based Vaccines and Therapeutics in North America
13.4.2. Total Market size of mRNA-based Vaccines and Therapeutics by Therapies in North America
13.5. Europe Market Size
13.5.1. Total Market size of mRNA-based Vaccines and Therapeutics in Europe
13.5.2. Total Market size of mRNA-based Vaccines and Therapeutics by Therapies in Europe
13.6. Asia
13.6.1. Total Market size of mRNA-based Vaccines and Therapeutics in Asia
13.6.2. Total Market size of mRNA-based Vaccines and Therapeutics by Therapies in Asia
13.7. ROW
13.7.1. Total Market size of mRNA-based Vaccines and Therapeutics in ROW
13.7.2. Total Market size of mRNA-based Vaccines and Therapeutics by Therapies in ROW
14. Market Access and Reimbursement of mRNA-based Vaccines and Therapeutics
15. Market Drivers
16. Market Barriers
17. Appendix
17.1. Bibliography
17.2. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
List of Table
Table 1 Total cases of selected indications for mRNA-based Vaccines and Therapeutics
Table 2 Total diagnosed cases of selected indications for mRNA-based Vaccines and Therapeutics
Table 3 Number of Patients Eligible for mRNA vaccines and therapeutics in North America
Table 4 Total treated cases of Targeted Indications Using mRNA Vaccines and Therapeutics in North America
Table 5 Total cases of selected indications for mRNA-based Vaccines and Therapeutics in Europe
Table 6 Total diagnosed cases of selected indications for mRNA-based Vaccines and Therapeutics in Europe
Table 7 Number of Patients Eligible for mRNA vaccines and therapeutics in Europe
Table 8 Total treated cases of Targeted Indications Using mRNA Vaccines and Therapeutics in Europe
Table 9 Total cases of selected indications for mRNA-based Vaccines and Therapeutics in Asia
Table 10 Total diagnosed cases of selected indications for mRNA-based Vaccines and Therapeutics in Asia
Table 11 Number of Patients Eligible for mRNA vaccines and therapeutics in Asia
Table 12 Total treated cases of Targeted Indications Using mRNA Vaccines and Therapeutics in
Table 13 Total cases of selected indications for mRNA-based Vaccines and Therapeutics in ROW
Table 14 Total diagnosed cases of selected indications for mRNA-based Vaccines and Therapeutics in ROW
Table 15 Number of Patients Eligible for mRNA vaccines and therapeutics in ROW
Table 16 Total treated cases of Targeted Indications Using mRNA Vaccines and Therapeutics in ROW
Table 17 Total Market Size of Global mRNA based Vaccines and therapeutics (2021 –2030)
Table 18 The market size of Global mRNA based Vaccines and Therapeutics Market by Therapies (2021–2030)
Table 19 Total Market Size of mRNA based Vaccines and therapeutics in North America (2021–2030)
Table 20 Market Size of mRNA based Vaccines and therapeutics by Therapies in North America (2021–2030)
Table 21 Total Market Size of mRNA based Vaccines and therapeutics in Europe (2021–2030)
Table 22 Market Size of mRNA based Vaccines and therapeutics by Therapies in Europe (2021–2030)
Table 23 Total Market Size of mRNA based Vaccines and therapeutics in Asia (2021–2030)
Table 24 Market Size of mRNA based Vaccines and therapeutics by Therapies in Asia (2021–2030)
Table 25 Total Market Size of mRNA based Vaccines and therapeutics in ROW (2021–2030)
Table 26 Market Size of mRNA based Vaccines and therapeutics by Therapies in ROW (2021–2030)
List of Figure
Figure 1 Total cases of selected indications for mRNA-based Vaccines and Therapeutics
Figure 2 Total diagnosed cases of selected indications for mRNA-based Vaccines and Therapeutics
Figure 3 Number of Patients Eligible for mRNA vaccines and therapeutics in North America
Figure 4 Total treated cases of Targeted Indications Using mRNA Vaccines and Therapeutics in North America
Figure 5 Total cases of selected indications for mRNA-based Vaccines and Therapeutics in Europe
Figure 6 Total diagnosed cases of selected indications for mRNA-based Vaccines and Therapeutics in Europe
Figure 7 Number of Patients Eligible for mRNA vaccines and therapeutics in Europe
Figure 8 Total treated cases of Targeted Indications Using mRNA Vaccines and Therapeutics in Europe
Figure 9 Total cases of selected indications for mRNA-based Vaccines and Therapeutics in Asia
Figure 10 Total diagnosed cases of selected indications for mRNA-based Vaccines and Therapeutics in Asia
Figure 11 Number of Patients Eligible for mRNA vaccines and therapeutics in Asia
Figure 12 Total treated cases of Targeted Indications Using mRNA Vaccines and Therapeutics in
Figure 13 Total cases of selected indications for mRNA-based Vaccines and Therapeutics in ROW
Figure 14 Total diagnosed cases of selected indications for mRNA-based Vaccines and Therapeutics in ROW
Figure 15 Number of Patients Eligible for mRNA vaccines and therapeutics in ROW
Figure 16 Total treated cases of Targeted Indications Using mRNA Vaccines and Therapeutics in ROW
Figure 17 Total Market Size of Global mRNA based Vaccines and therapeutics (2021 –2030)
Figure 18 The global Market size of mRNA based Vaccines and therapeutics by Therapies (2021–2030)
Figure 19 Total Market Size of mRNA based Vaccines and therapeutics in North America (2021–2030)
Figure 20 Market Size of mRNA based Vaccines and therapeutics by Therapies in North America (2021–2030)
Figure 21 Total Market Size of mRNA based Vaccines and therapeutics in Europe (2021–2030)
Figure 22 Market Size of mRNA based Vaccines and therapeutics by Therapies in Europe (2021–2030)
Figure 23 Total Market Size of mRNA based Vaccines and therapeutics in Asia (2021–2030)
Figure 24 Market Size of mRNA based Vaccines and therapeutics by Therapies in Asia (2021–2030)
Figure 25 Total Market Size of mRNA based Vaccines and therapeutics in ROW (2021–2030)
Figure 26 Market Size of mRNA based Vaccines and therapeutics by Therapies in ROW (2021–2030)
Translate Bio
AstraZeneca/Moderna
CureVac
BioNTech/Roche (Genentech)
BioNTech/Sanofi
Moderna
CureVac
Arcturus
